Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

Early Phase 1

Completed

Conditions: Proliferative Vitreoretinopathy

Interventions: Drug: Adrenocorticotropic Hormone

First Posted Date: 2018-11-01

Last Posted Date: 2023-08-08

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 11

Registration Number: NCT03727776

Locations: 🇺🇸
Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

Phase 4

Terminated

Conditions: Panuveitis
Uveitis, Posterior
Uveitis, Intermediate

Interventions: Drug: Acthar Gel

First Posted Date: 2018-09-04

Last Posted Date: 2021-08-03

Lead Sponsor: Mallinckrodt

Target Recruit Count: 5

Registration Number: NCT03656692

Locations: 🇺🇸
Blue Ocean Clinical Research, Clearwater, Florida, United States
🇺🇸
Bergstrom Eye Research, LLC, Fargo, North Dakota, United States
🇺🇸
Valley Retina Institute, PA, McAllen, Texas, United States

and more 5 locations

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Conditions: Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function

First Posted Date: 2018-08-23

Last Posted Date: 2020-02-05

Lead Sponsor: Greater Boston Medical Associates

Target Recruit Count: 40

Registration Number: NCT03644771

Locations: 🇺🇸
Greater Boston Medical Associates 211 West St., Milford, Massachusetts, United States

The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis

Phase 3

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Acthar Injectable Product
Drug: Depo medrol

First Posted Date: 2018-04-30

Last Posted Date: 2024-01-30

Lead Sponsor: Attune Health Research, Inc.

Target Recruit Count: 6

Registration Number: NCT03511625

Locations: 🇺🇸
Attune Health, Beverly Hills, California, United States

(ACTH) for the Treatment of Sarcoid Uveitis

Conditions: Sarcoid Uveitis

Interventions: Drug: H.P. Acthar gel

First Posted Date: 2018-03-22

Last Posted Date: 2018-03-22

Lead Sponsor: John Huang, MD

Target Recruit Count: 10

Registration Number: NCT03473964

Locations: 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis

Phase 2

Recruiting

Conditions: Scleritis

Interventions: Drug: ACTH (adrenocorticotropic hormone) gel

First Posted Date: 2018-03-14

Last Posted Date: 2023-10-23

Lead Sponsor: Metropolitan Eye Research & Surgery Institute

Target Recruit Count: 30

Registration Number: NCT03465111

Locations: 🇺🇸
Byers Eye Institute, Stanford University, Palo Alto, California, United States
🇺🇸
Foresight Studies, LLC, San Antonio, Texas, United States
🇺🇸
Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: ACTHar

First Posted Date: 2018-02-05

Last Posted Date: 2021-08-31

Lead Sponsor: IRIS Research and Development, LLC

Target Recruit Count: 10

Registration Number: NCT03419650

Locations: 🇺🇸
IRIS Research and Development, Plantation, Florida, United States

ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children

Phase 4

Withdrawn

Conditions: Steroid-Resistant Nephrotic Syndrome

Interventions: Drug: Acthar Gel 80 UNT/ML Injectable Solution

First Posted Date: 2018-01-24

Last Posted Date: 2019-04-23

Lead Sponsor: Rhode Island Hospital

Registration Number: NCT03408405

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Phase 4

Withdrawn

Conditions: Keratoconjunctivitis Sicca

Interventions: Drug: repository corticotropin injection

First Posted Date: 2018-01-12

Last Posted Date: 2018-12-14

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT03398018

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Acthar Gel in Participants With Pulmonary Sarcoidosis

Phase 4

Completed

Conditions: Sarcoidosis, Pulmonary

Interventions: Drug: Acthar Gel
Drug: Placebo

First Posted Date: 2017-10-25

Last Posted Date: 2023-02-27

Lead Sponsor: Mallinckrodt

Target Recruit Count: 55

Registration Number: NCT03320070

Locations: 🇺🇸
Central Florida Pulmonary Group PA, Orlando, Florida, United States
🇺🇸
Valley Medical Group, Ridgewood, New Jersey, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 26 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy